![Pierre de Waha](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Pierre de Waha
Director/Board Member at Cellaïon SA
Pierre de Waha active positions
Companies | Position | Start | End |
---|---|---|---|
Invest.BW SA
![]() Invest.BW SA Investment ManagersFinance Societe de Developpement et de Participation du Brabant Wallon SA (Invest.BW) is a private equity and venture capital firm founded in 1987. Invest.BW SA is headquartered in Louvain-la-Neuve. | Private Equity Investor | 01/04/2007 | - |
GreenWatt SA
![]() GreenWatt SA Electric UtilitiesUtilities GreenWatt SA designs and installs on-site bio-methanization plants. It engages in the provision of renewable energy and recycling solutions for waste bio-methanization cogeneration. The company was founded by Marc-Jean Spiltoir, Patrick Alexandre Thierry Rene van den Broucke, and Therese Marie Wathelet Florence in 2004 and is headquartered in Louvain-la-Neuve, Belgium. | Director/Board Member | - | - |
Cellaïon SA
![]() Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Director/Board Member | - | - |
Career history of Pierre de Waha
Former positions of Pierre de Waha
Companies | Position | Start | End |
---|---|---|---|
BNP Paribas Fortis Private Equity Belgium NV
![]() BNP Paribas Fortis Private Equity Belgium NV Investment ManagersFinance BNP Paribas Fortis Private Equity Belgium NV is a Private Equity/Venture Capital firm, a subsidiary of BNP Paribas Fortis SA/NV founded in 1981. BNP Paribas Fortis Private Equity Belgium NV is headquartered in Brussels. | Private Equity Investor | - | 20/02/2007 |
Statistics
International
Belgium | 5 |
Operational
Private Equity Investor | 2 |
Director/Board Member | 2 |
Sectoral
Finance | 3 |
Utilities | 2 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 4 |
---|---|
BNP Paribas Fortis Private Equity Belgium NV
![]() BNP Paribas Fortis Private Equity Belgium NV Investment ManagersFinance BNP Paribas Fortis Private Equity Belgium NV is a Private Equity/Venture Capital firm, a subsidiary of BNP Paribas Fortis SA/NV founded in 1981. BNP Paribas Fortis Private Equity Belgium NV is headquartered in Brussels. | Finance |
Invest.BW SA
![]() Invest.BW SA Investment ManagersFinance Societe de Developpement et de Participation du Brabant Wallon SA (Invest.BW) is a private equity and venture capital firm founded in 1987. Invest.BW SA is headquartered in Louvain-la-Neuve. | Finance |
GreenWatt SA
![]() GreenWatt SA Electric UtilitiesUtilities GreenWatt SA designs and installs on-site bio-methanization plants. It engages in the provision of renewable energy and recycling solutions for waste bio-methanization cogeneration. The company was founded by Marc-Jean Spiltoir, Patrick Alexandre Thierry Rene van den Broucke, and Therese Marie Wathelet Florence in 2004 and is headquartered in Louvain-la-Neuve, Belgium. | Utilities |
Cellaïon SA
![]() Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Pierre de Waha
- Experience